| Literature DB >> 30340339 |
Karolina Dziąbowska1,2, Elżbieta Czaczyk3,4, Dawid Nidzworski5,6.
Abstract
The basic affairs connected to the influenza virus were reviewed in the article, highlighting the newest trends in its diagnostic methods. Awareness of the threat of influenza arises from its ability to spread and cause a pandemic. The undiagnosed and untreated viral infection can have a fatal effect on humans. Thus, the early detection seems pivotal for an accurate treatment, when vaccines and other contemporary prevention methods are not faultless. Public health is being attacked with influenza containing new genes from a genetic assortment between animals and humankind. Unfortunately, the population does not have immunity for mutant genes and is attacked in every viral outbreak season. For these reasons, fast and accurate devices are in high demand. As currently used methods like Rapid Influenza Diagnostic Tests lack specificity, time and cost-savings, new methods are being developed. In the article, various novel detection methods, such as electrical and optical were compared. Different viral elements used as detection targets and analysis parameters, such as sensitivity and specificity, were presented and discussed.Entities:
Keywords: ELISA; PCR; Rapid Influenza Diagnostic Tests RIDTs; electrochemical detection; influenza virus; optical detection
Mesh:
Year: 2018 PMID: 30340339 PMCID: PMC6315519 DOI: 10.3390/bios8040094
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Conventional methods of influenza virus detection.
| Rapid Diagnostic Tests | Immunofluores-Cence Assays | Serological Assays | Cell Culture Based Detection | Nucleic Acid-Based Tests | Next-Generation Sequencing Based Methods |
|---|---|---|---|---|---|
| Alere TM and Influenza A&B | direct fluorescent antibody staining | hemagglutina-tion inhibition | Immunofluores-cence microscopy | reverse transcriptase-PCR | Sanger method |
| BD Veritor TM | indirect fluorescent antibody staining | virus neutralization | antibody staining | sequencing-based tests like NGS | Illumina Platform |
| Sofia® Influenza A + B | single radial hemolysis | erythrocytes hemadsorption | ligase chain reaction | Roche 454 Life Sciences | |
| the cobas® Liat® Influenza A/B | complement fixation | DNA microarray tests | Pacific Bioscience | ||
| BUDDITM Influenza | ELISA | SAMBA | Ion Proton | ||
| Quick Navi-FluTM | Western blotting | NASBA | Complete Genomics | ||
| LAMP | Luminex |
Figure 1RIDT mode of action: (a) Bounding dye-labeled antibodies specific for target antigen onto the nitrocellulose strip; (b) Addition of respiratory specimen with buffer to the strip; (c) Trapping antibodies on the test line if target antigen is presented. Reproduced with permission from WHO on behalf of the Special Programme for Research and Training in Tropical Diseases, Use of Influenza Rapid Diagnostic Tests; published by WHO Library Cataloguing-in-Publication Data, 2010.
Figure 2Different approaches for influenza virus detection: (a) Reuse of known devices like glucometers; (b) Electrical detection system; (c) Strip-based sensor/ ELISA modifications; (d) Optical approaches using nanoparticles.
Figure 3An example of electrode surface modification. Boron-doped diamond electrode modified via click reaction for infectious flacherie virus (IFV) electrochemical detection. Reproduced with permission from Matsubara et al., PNAS; published by PNAS, 2016.
Figure 4Novel Isoprene Sensor readout with Bluetooth mode. Reproduced with permission from Gouma et al., Sensors; published by MPDI, 2017.
Comparison of novel detection methods of influenza virus.
| Detection Method | Target Molecule | LOD | Linear Range | Detection Time | Reference |
|---|---|---|---|---|---|
|
| |||||
| microfluidic RT-PCR + DEP chip | DNA | 5.36 × 103 copies/mL | 5.36 × 103–5.36 × 105 copies/mL | 15 min | [ |
|
| |||||
| smartphone-based fluorescence | VP | 7.5 PFU/mL | 0.94 × 100–4.8 × 102 PFU/mL | 15 min | [ |
|
| |||||
| EIS | M1 | 1 fg/mL | 1–100 fg/mL | 5 min | [ |
| dielectrophoresis | VP | 0.25 pg/mL | 1:100 000 dilution factor | 30 s | [ |
| LSV | NA | 5.6 ng/mL | 0–900 ng/mL | 30 min | [ |
| DPV | PB1-F2 | 0.42 nM | 50–300 nM; 0.5–1.5 mM | - | [ |
|
| |||||
| spectrophotometry | VP | 0.04 ng/mL | 0.1–4.0 ng/mL | 30 min | [ |
| SERS + LFA | VP | 1.9 × 104 PFU/mL | 0–1.0 × 106 PFU/mL | - | [ |
| LRET | HA | 7 pM | 10 pM to 10 nM | 2 h | [ |
| NIR | RNA | 1 copy/mL | 0–14 copies/mL | 3 min | [ |
|
| |||||
| RT-SIBA | RNA | 100 copies | - | <30 min | [ |
| mRT-LAMP-CIRN | RNA | 101/102 copies | 104–100 RNA copies/μL | ~30 min | [ |
|
| |||||
| SAW | HA | 1 ng/mL | 1–100 ng/mL | 10 min | [ |
| GMR | NP | 1.5 × 102 TCID50/mL | 1.5 × 102–1.0 × 105 TCID50/mL | 60 min | [ |
| SD-TIRS + TG | DNA | 74 zM | 74 zM–7.4 fM | 50 ms | [ |
| conductance | DNA | 5 pM | 10 pM–100 nM | 1 h | [ |
| ECL | HA-P | 2.7 × 102 PFU/mL | 2.7 × 102–2.7 × 103 PFU/mL | 1 h | [ |
| CFT + CL | RP | 0.14 fg/mL | 0.25 fg/mL–25 ng/Ml | 2.5 h | [ |
| CNTFET | DNA | 1 pM | 1 pM–10 nM | 2 h | [ |
VP—viral particles, NIR—near-infrared fluorescence, HA-P—hemagglutinin peptide, RP—recombinant protein, LSV linear sweep voltammetry, SERS + LFA-surface-enhanced Raman scattering—based lateral flow assay, RT-SIBA—reverse transcription strand invasion-based amplification, mRT-LAMP-CIRN—reverse transcription loop-mediated isothermal amplification-based assay coupled with cascade invasive reaction, CFT + CL—complement fixation test+ luminol chemiluminescence.